2020
The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation.
Laws A, Pastorello R, Choi J, Kantor O, Grossmith S, Schnitt S, Golshan M, Mittendorf E, King T. The impact of pattern of tumor response and other post-treatment histologic features on local recurrence in patients treated with neoadjuvant chemotherapy and breast conservation. Journal Of Clinical Oncology 2020, 38: 581-581. DOI: 10.1200/jco.2020.38.15_suppl.581.Peer-Reviewed Original ResearchPathologic complete responseResidual invasive diseaseLocal recurrenceNeoadjuvant chemotherapyBreast-conserving surgeryResidual DCISTumor responseResidual diseaseInvasive diseaseBreast pathologic complete responseDetailed pathology reviewAdjuvant endocrine therapyPoor prognostic factorModern systemic therapyTreatment effectsNeoadjuvant trastuzumabRCB scoreEndocrine therapyFree survivalMulticentric diseaseBreast conservationComplete responseLymphovascular invasionMargin statusPrognostic factors
2013
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations